Intra-operative blood loss during Endoscopic sinus surgery in patient with Chronic Rhinosinusitis with Nasal Polyp Oral Tranexamic Acid, TXA, Oral TXA, CRSwNP, Chronic rhinosinusitis with Nasal Polyp, Endoscopic Sinus Surgery, ESS
Conditions
Interventions
Placebo 2 tabs po q 6 hr for 4 doses,Oral Tranexamic Acid (500 mg) 2 tabs po q 6 hr for 4 doses
Placebo,Oral Tranexamic Acid
Sponsors
None
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 to 65 years who receive treatment at the Otolaryngology outpatient department, Department of Otolaryngology, Phramongkutklao Hospital. 2. Patients who consent to participate in the research study. 3. Patients diagnosed with chronic rhinosinusitis with nasal polyps. 4. Patients who are scheduled to undergo functional endoscopic sinus surgery. 5. Patients with ASA physical status class 1 or 2.
Exclusion criteria
Exclusion criteria: 1. Patients younger than 18 years. 2. Patients who do not consent to participate in the research study. 3. Patients with ASA physical status class 3 or higher. 4. Patients with a history of thromboembolic disease. 5. Patients with a history of allergic reactions or contraindications to tranexamic acid. 6. Patients with abnormal liver function or a history of liver disease with AST/ALT more than 3 times the upper normal limit. 7. Patients with kidney disease or a history of chronic kidney disease with ESRD or eGFR < 30. 8. Patients with blood disorders or on anticoagulants or antiplatelet medications that cannot be discontinued prior to surgery. 9. Patients with other conditions that may increase the risk of bleeding complications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bood loss Intra-operative Millilitres | — |
Secondary
| Measure | Time frame |
|---|---|
| Surgical field quality Intra-operative Boezaart surgical field grading scale | — |
Countries
Thailand
Contacts
Public ContactThanit Chalermwattanachai
Doctor
Outcome results
None listed